(October 27, 2016, 1:16 PM EDT) -- BOSTON — Plaintiffs in the Zofran birth defect multidistrict litigation on Oct. 26 asked the court to strike defendant GlaxoSmithKline LLC’s (GSK) motion to dismiss certain cases on the issue of innovator liability and for failure to plead fraud claims (In Re:  Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 2657, No. 15-md-2657, D. Mass.).

(Motion available.  Document #28-161103-017M.)

Zofran is an anti-nausea drug approved to treat cancer patients undergoing chemotherapy.  Plaintiffs allege that GSK marketed the drug off-label to treat morning sickness in pregnant women...